Pfizer Quality Improvement Request for Proposals: Implementing and Scaling System-Level Solutions for the HRRm Testing Pathway in Metastatic Prostate Cancer
Pfizer Inc. funds quality improvement projects to enhance and scale system-level solutions for HRRm testing in metastatic prostate cancer, focusing on workflow, coordination, and measurable clinical impact.
Funder: Pfizer Inc.
Due Dates: October 7, 2026: Submission Deadline
Funding Amounts: Up to $100,000 USD per project; total available budget approximately $200,000 USD; project duration up to 18 months.
Summary: Funds multidisciplinary quality improvement initiatives to implement and scale system-level solutions for HRRm testing in metastatic prostate cancer, aiming to improve workflow efficiency and patient access globally (ex-US).
Description
This Pfizer Quality Improvement grant supports practice-based initiatives focused on overcoming key barriers in the Homologous Recombination Repair mutation (HRRm) testing pathway for metastatic prostate cancer (mPC). The program seeks to fund projects that re-engineer clinical workflows to deliver more efficient, reliable, and standardized HRRm testing, with an emphasis on reducing administrative burden and improving care coordination in both academic and community settings. Proposals must emphasize sustainable, system-level interventions that demonstrate measurable improvements in HRRm testing rates, testing continuity, result utilization, or care coordination. The intent is to support scalable solutions that can be implemented across diverse healthcare environments.
